N/A
Completed N=248
Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle
Source: ClinicalTrials.gov NCT03267264 ↗Enrolled (actual)
248
Serious AEs
0.6%
Results posted
Jul 2019
Primary outcomePrimary: Overall User Preference -Combined Groups — 17.5 mm
Summary
This is a multi-site, prospective, open-label, randomized, 2 period cross over study comparing the subjects' current 32G pen needle (four groups of pen needles) to the BD Nucleus pen needle. The study will consist of two 15 day periods ( in which the subject will use each pen needle [BD Nucleus pen needle or subject's current pen needle, order randomized] for injection. At the end of the last study period, each subject will be asked to evaluate his or her perceptions using a 150mm relative VAS scale.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall User Preference -Combined Groups |
17.5 | — |
| SECONDARY Overall User Preference - Each Comparator Group |
30.5; 20.6; 6.2; 12.8 | — |
| SECONDARY User Experience - All Study Groups Combined |
18.0; 15.9; 15.5; 19.7 | — |
| SECONDARY User Experience - Each Individual Study Group |
27.8; 20.7; 8.4; 15.1; 20.2; 19.4 | — |
Eligibility Criteria
Inclusion Criteria
- Adults (18 - 75 inclusive)
- Diagnosed Type 1 or Type 2 diabetes
- Every effort will be made to recruit approximately 25% Type 1 patients (of the total population, not of each subgroup) (minimum: 10%, maximum: 50%)
- Every effort will be made to recruit a minimum of 30 subjects with Asian ethnicity (of the total population, not of each subgroup). Ideally, 60 Asian subjects are needed for the study
- Minimum within the last 4 months experience self-injecting insulin with a pen injector
- Minimum within the last 2 months experience self-injecting consistently with one of the following available pen needles OR a subject may be enrolled that is using a 31G/32G pen needle that is not longer than 6mm in length who is willing to transfer to one of the following 32G pen needle with a 14 day wash-in period:
- BD Nano™ 32Gx4mm
- NovoFine® 32Gx6mm
- NovoTwist® 32Gx5mm or
- NovoFine® Plus 32Gx4mm
- Owen Mumford PenTips 32Gx4mm or
- Perrigo / Ypsomed ClickFine 32Gx4mm or
- Other 32G such as UltiMed, MHC, or other private label.
- Able and willing to provide informed consent/participant form
- Able and willing to complete all study procedures
Exclusion Criteria
- Self-injecting insulin with a pen injector for less than 3 months
- Planned changes in insulin regimen (increasing or decreasing number of injections per day).
- Positive pregnancy test (urine)
- Currently taking anti-platelet therapy or anticoagulants (Use of up to 81 mg per day of aspirin is permitted).
- History of a bleeding disorder or easy bruising
- Blood borne infection(s)
- History of recurrent dermatological conditions or skin disorder (e.g., psoriasis, eczema)
- Gross skin anomalies and abnormalities (e.g., scars, stretch marks, discolorations, tattoos, superficial masses, acne, inflammation) located at or very close to the injection sites
- Fear of needles, history of symptomatic low blood pressure or history of fainting (syncope) during hypodermic injections.
- Use of any prescription analgesic medications within 24 hours of first study injection, and during the study.
- A current or previous medical or physical condition that, in the opinion of the investigator, would place the patient at risk or make them unable to perform study procedures or has the potential to confound interpretation of the study results.
- Currently participating in another study
- Employed by, or currently serving as a contractor or consultant to BD or any insulin, insulin pen, or insulin pen needle manufacturer
Data sourced from ClinicalTrials.gov (NCT03267264). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.